A
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Gastrointestinal Cancers
- Tumour Sub-type
- Gastric or gastro-oesophageal junction adenocarcinoma
- Tumour stage
- Early
- Control Arm
- Surgery
- Treatment Setting
- Peri-operative resectable gastric or gastroesophageal junction adenocarcinoma
- Trial Name
- MAGIC
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Evaluated Outcome
- OS
- Form(s)
- Form 1
Outcome Data
- OS Control
- 5-year survival 23%
- OS Gain
- 13%
- OS HR
- 0.75 (0.60-0.93)
Final Score (after adjustments)
- Final curative score
- A
- Issue date
- 11.12.2018
- Last update
- 08.02.2022
ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression